Prelude Therapeutics To Participate in Jefferies Healthcare Conference

About this update from Prelude Therapeutics Incorporated

WILMINGTON, Del. , May 31, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference , taking place in New York City , June 7 to 9, 2023 . Details are as follows: On Wednesday, June 7th, at 8:00 a.m. ET , Kris Vaddi , Ph.D., CEO of Prelude will participate in a fireside chat . The live webcast is available here and will be available for replay for 90 days. Dr. Vaddi , joined by Jane Huang , MD, President and Chief Medical Officer and Laurent Chardonnet , Chief Financial Officer , will host one-on-one meetings on June 7th . About Prelude Prelude is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. Prelude’s diverse pipeline is comprised of highly differentiated, potentially best-in-class proprietary small molecule compounds aimed at addressing clinically validated pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and highly selective CDK9 inhibitor; PRT3645, a brain penetrant CDK4/6 inhibitor; and PRT3789 a first-in-class SMARCA2/BRM protein degrader. For more information, visit our website and follow us on LinkedIn and Twitter . Investor Contact: Lindsey Trickett Vice President, Investor Relations240.543.7970 [email protected] Media Contact: Helen Shik Shik Communications 617.510.4373 [email protected] Source: Prelude Therapeutics, Inc.

View stock analysis, news, and events for Prelude Therapeutics Incorporated